HuMNC2-CAR22 is under clinical development by Minerva Biotechnologies and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HuMNC2-CAR22’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HuMNC2-CAR22 overview

huMNC2-CAR22 (MUC1*-CAR-1XX) is under development for the treatment of human epidermal growth factor receptor 2 positive breast cancer (HER2+ breast cancer), human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer) and triple-negative breast cancer (TNBC). The therapeutic candidate comprises autologous T cells engineered to express chimeric antigen receptor (CAR) targeting cells expressing MUC1* (muk 1 star).

Minerva Biotechnologies overview

Minerva Biotechnologies (Minerva) operates as a cancer therapy and regenerative medicine company that develops immunotherapies and cancer drugs. The company provides antibody for T-cell immunotherapy, which is used in advanced breast and ovarian cancers; and humanized antibodies used for prostate and breast cancer. It offers anti-metastasis antibody that block the metastatic growth factor and transition from a regular cancer cell to a metastatic cancer cell. Minerva‘s stem cell technology is utilized to generate human naive state induced pluripotent stem cells using a single, naturally occurring human stem cell growth factor for the treatment of cancer. The company’s technology is also used to facilitate regenerative therapies targeting diseases of the heart, central nervous system, liver, diabetes, and macular degeneration. Minerva is headquartered in Waltham, Massachusetts, the US.

For a complete picture of HuMNC2-CAR22’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.